To determine upstream factors contributing to the activation of MEK, we evaluated the activity status of SFKs, which have been shown to be activated in imatinib and dasatinib‐resistant CML patient samples (Hayette et al., 2011). Here, MAP2K7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.